Objective:To investigate the impact of the number of examined lymph nodes (ELN) on survival outcomes in gastric cancer patients with postoperative pathological stage pN3b.Methods:This retrospective cohort study included 279 pN3b gastric cancer patients who underwent D2 gastrectomy at Nanfang Hospital, Southern Medical University (September 2008 to April 2023), with 35 patients receiving combination chemotherapy and anti-PD-1 therapy (immunotherapy group) and 244 receiving adjuvant chemotherapy alone (nonimmunotherapy group). Additionally, 422 patients with pN3b from the SEER database (2005 to 2020) were collected as an external validation cohort to determine the optimal cutoff value for the number of lymph nodes examined in the nonimmunotherapy group. The primary endpoints were overall survival (OS) and recurrence-free survival (RFS) in the nonimmunotherapy group of the Nanfang Hospital cohort, stratified by whether the number of examined lymph nodes was above or below the ELN optimal cutoff value. These findings were subsequently validated in the SEER cohort.Results:The optimal ELN cutoff value (34 nodes) was determined using X-tile software and by constructing an ELN-HR fitting model with inflection point identification. In the nonimmunotherapy group, patients with ELN >34 exhibited significantly prolonged survival compared to ELN ≤34 (median OS: 25.0 (95%CI:20.5-29.5) to 17.0 (95%CI:12.7-21.3) months, P=0.004; median RFS: 19.0 (95%CI:15.6-22.4) to 13.0 (95%CI:9.5-16.5) months, P=0.048). Multivariate Cox analysis also showed ELN >34 to be an independent protective factor for both OS (HR=0.576, 95%CI: 0.397-0.836) and RFS (HR=0.701, 95%CI: 0.492-0.998). In the SEER cohort, ELN >34 was associated with a 5-month OS extension (19 to 14 months, P=0.065), with multivariate analysis supporting its independent prognostic significance (HR=0.729, 95%CI: 0.580-0.915, P=0.006). Notably, in the immunotherapy group, patients with ELN >34 ( n=30) achieved a median OS of 41 months, but the median OS had not been reached in the ELN ≤34 group ( n=5) (1 death at 48 months). Conclusion:Higher ELN (>34) correlates with improved survival in nonimmunotherapy-treated pN3b gastric cancer patients. However, in pN3b gastric cancer patients treated with immunotherapy, the optimal ELN threshold requires further exploration to determine.

Objective:To investigate the impact of the number of examined lymph nodes (ELN) on survival outcomes in gastric cancer patients with postoperative pathological stage pN3b.Methods:This retrospective cohort study included 279 pN3b gastric cancer patients who underwent D2 gastrectomy at Nanfang Hospital, Southern Medical University (September 2008 to April 2023), with 35 patients receiving combination chemotherapy and anti-PD-1 therapy (immunotherapy group) and 244 receiving adjuvant chemotherapy alone (nonimmunotherapy group). Additionally, 422 patients with pN3b from the SEER database (2005 to 2020) were collected as an external validation cohort to determine the optimal cutoff value for the number of lymph nodes examined in the nonimmunotherapy group. The primary endpoints were overall survival (OS) and recurrence-free survival (RFS) in the nonimmunotherapy group of the Nanfang Hospital cohort, stratified by whether the number of examined lymph nodes was above or below the ELN optimal cutoff value. These findings were subsequently validated in the SEER cohort.Results:The optimal ELN cutoff value (34 nodes) was determined using X-tile software and by constructing an ELN-HR fitting model with inflection point identification. In the nonimmunotherapy group, patients with ELN >34 exhibited significantly prolonged survival compared to ELN ≤34 (median OS: 25.0 (95%CI:20.5-29.5) to 17.0 (95%CI:12.7-21.3) months, P=0.004; median RFS: 19.0 (95%CI:15.6-22.4) to 13.0 (95%CI:9.5-16.5) months, P=0.048). Multivariate Cox analysis also showed ELN >34 to be an independent protective factor for both OS (HR=0.576, 95%CI: 0.397-0.836) and RFS (HR=0.701, 95%CI: 0.492-0.998). In the SEER cohort, ELN >34 was associated with a 5-month OS extension (19 to 14 months, P=0.065), with multivariate analysis supporting its independent prognostic significance (HR=0.729, 95%CI: 0.580-0.915, P=0.006). Notably, in the immunotherapy group, patients with ELN >34 ( n=30) achieved a median OS of 41 months, but the median OS had not been reached in the ELN ≤34 group ( n=5) (1 death at 48 months). Conclusion:Higher ELN (>34) correlates with improved survival in nonimmunotherapy-treated pN3b gastric cancer patients. However, in pN3b gastric cancer patients treated with immunotherapy, the optimal ELN threshold requires further exploration to determine.

Objective China has the biggest population of commonly encountered liver diseases , so hepatology resear-ches are of great importance to human health .In order to comprehensively collect/organize and effectively share/display liv-er physiopathology knowledge scattered around databases and literature , a Human Liver Disease Ontology ( HuLDO ) is built and applied in many ways .Methods HuLDO systematically classified and annotated various human liver diseases based on extensive cross mapping and integration of several authoritative nomenclatures of diseases and two monographs of hepatology .Results In the present version , HuLDO encompassed knowledge of 227 human liver diseases and was enriched by plenty of synonyms,definitions, descriptions, references, and logical or pathological relations between different disea-ses.Compared with other existing nomenclatures , HuLDO extended far beyond them in the scope of liver diseases .Several applications of HuLDO in database construction , knowledge collection and text mining were also described .Conclusion HuLDO offers a sound basis for knowledge mining , data integration and data analysis in the field of hepatology .HuLDO is publicly available at ftp://liveratlas.hupo.org.cn/5.liver 5.liver%20Disease%20Ontology/.

Objective To study the mechanism of Shoucong to prevent and cure Alzheimer's disease by observing the effect of shoucong capsule on total autioxidative capacity (TAOC), Lipofuscin (LIP) in AD rat brain tissue and blood, and brain tissue pathological changes. Methods Male wistar rats were randomly divided into 5 group:blank compared group, model compared group, Naofukang group, Shoucong Capsule (low, high dose) group. AD compound model rats were made by injected with D-galactose on the neck of rats, then injected with scopolamine in the intraperiton of rats. They were prevented and cured with Shoucong Capsule. TAOC, LIP level in rat brain tissue and blood were examined with spectroscopic analysis, brain tissue pathological changes were observed under light microscope. Results Compared with AD model group, Shoucong Capsule enhanced TAOC level in rat brain tissue and blood, deceased LIP level in rat brain tissue, and lessened the pathological injury of dementia rats. Conclusions Enhancing TAOC level and deceasing LIP level in brain tissue and blood may be one of the mechanism for Shoucong Capsule to prevent and cure Alzheimer's disease.

Objective To study effects of Shoucong capsule on the learning-memorial ability,CAT and MAO activities in brain tissue of AD rat.Methods Male Wistar rats were randomly divided into 5 group:blank compared group,model compared group,Naofukang group and Shoucong capsule(low,high dose) group,every group contained 9 rats.They were injected with D-galactose into the neck and injected with scopolamine into the intraperiton to making AD compound model rats.The learning-memorial ability were examined by diving-stand test,and CAT and MAO activities in brain tissue were determined by spectrophotometry.Results Shoucong capsule greatly deceased error time and enhanced the electric latent period,and enhanced the activities of CAT while deceased the activities of MAO in model rats.Conclusions Shoucong capsule has significantly effect of preventing and treating senile dementia in AD rats by enhancing the activities of CAT and deceasing the activities of MAO in brain tissue.